Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Stereotactic surgery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Stereotactic surgery. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2017-000133-31 Sponsor Protocol Number: AGO/2017/001 Start Date*: 2017-07-31
    Sponsor Name:UZ Gent
    Full Title: Combined hypofractionated stereotactic body radiotherapy with immunomodulating systemic therapy for inoperable recurrent head and neck cancer: detection of the maximum tolerated dose.
    Medical condition: local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx in previously irradiated tissue, with former irradiation with cu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005225-37 Sponsor Protocol Number: 16-12301 Start Date*: 2018-08-10
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: The ASTEROID trial - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patien...
    Medical condition: Stage I Non-small cell lung cancer (NSCLC) that has been treated with Stereotactic Body Radiotherapy (SBRT).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007349-30 Sponsor Protocol Number: ML21873 Start Date*: 2009-04-15
    Sponsor Name:ROCHE
    Full Title: Open-label, phase II, randomized, comparative, multicentre trial of concurrent Whole Brain Radiation Therapy (WBRT) and capecitabine (Xeloda®) followed by maintenance capecitabine compared with sta...
    Medical condition: Female breast cancer patients with newly diagnosed CNS metastases with at least one brain lesion measuring ≥0.5 cm in longest dimension, who are not considered candidates for surgery or stereotacti...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-002599-35 Sponsor Protocol Number: 2022-1-58-002 Start Date*: 2022-10-21
    Sponsor Name:Centre de Lutte Contre le Cancer Eugène Marquis
    Full Title: Contribution of [18F]DPA-714 PET for grading and exploration of the inflammatory microenvironment of glioma, a pilot study.
    Medical condition: glioma (grade OMS II à IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002417-21 Sponsor Protocol Number: AK2016-2 Start Date*: 2016-09-22
    Sponsor Name:Rigshospitalet
    Full Title: uPAR-PET/MR in glioma
    Medical condition: Gliomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-005187-34 Sponsor Protocol Number: CCR4644 Start Date*: 2017-09-11
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: Stereotactic body radiotherapy with immunotherapy in early stage non-small cell lung cancer: tolerability and lung effects
    Medical condition: Non small-cell lung cancer (NSCLC) Stage: T1-3( ≤5cm)N0M0)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-001939-88 Sponsor Protocol Number: IRST157.04 Start Date*: 2023-02-17
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Phase II study of Gemcitabine plus Nab-Paclitaxel in combination with Losartan followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer
    Medical condition: Unresectable locally advanced, non-metastatic pancreatic cancer (as described by NCCN guidelines version 1.2022)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003011-22 Sponsor Protocol Number: ETOP_14-18 Start Date*: 2019-10-10
    Sponsor Name:ETOP (European Thoracic Oncology Platform)
    Full Title: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the prima...
    Medical condition: Synchronous oligo-metastatic Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001109-26 Sponsor Protocol Number: PS1/001/07 Start Date*: 2010-11-04
    Sponsor Name:Oxford BioMedica (UK) Ltd
    Full Title: A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease
    Medical condition: Patients with bilateral, idiopathic Parkinson's Disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023837-45 Sponsor Protocol Number: BRF113929 Start Date*: 2011-01-26
    Sponsor Name:GlaxoSmithKline
    Full Title: BRF113929: A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to...
    Medical condition: BRAF V600E or V600K mutation-positive metastatic melanoma to the brain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004614-10 Sponsor Protocol Number: CA209-429 Start Date*: 2017-06-12
    Sponsor Name:University Hospital Tübingen
    Full Title: An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma
    Medical condition: Patients with stage IV melanoma and four or more symptomatic brain metastases, who are not eligible for surgery or radiosurgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002572-41 Sponsor Protocol Number: D9103C00001 Start Date*: 2019-03-08
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresec...
    Medical condition: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001614-16 Sponsor Protocol Number: 16TETE04 Start Date*: 2016-09-22
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma.
    Medical condition: Recurrent glioblastoma.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003513-14 Sponsor Protocol Number: DC1 Start Date*: 2009-05-20
    Sponsor Name:Department of Neurology, Karolinska University Hospital [...]
    1. Department of Neurology, Karolinska University Hospital
    2. Dept. of Pediatric hematology and oncology, Astrid Lindgren Children´s Hosp,Karolinska Univ Hospital
    Full Title: Imune therapy of High Grade Glioma with dendritic cell vaccination. A phase II study.
    Medical condition: High grade glioma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003873-41 Sponsor Protocol Number: 14-23-16/07 Start Date*: 2015-07-09
    Sponsor Name:MAASTRO Clinic
    Full Title: Non invasive imaging of tumor hypoxia with [18F]HX4 Positron-Emission-Tomography (PET): A phase II trial
    Medical condition: Eligible patients with histologically/cytologically proven primary tumors of the prostate, esophagus, brain or rectum or metastatic disease to the brain (originating from breast, lung or colorectal...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001378-13 Sponsor Protocol Number: 001 Start Date*: 2017-02-02
    Sponsor Name:University Hospital Wuerzburg
    Full Title: A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia.
    Medical condition: cervical dystonia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10064124 Cervical dystonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003827-31 Sponsor Protocol Number: ICO-N-2017-08 Start Date*: 2018-07-16
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trial
    Medical condition: oligometastatic hormone sensitive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007463 Carcinoma prostatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004344-78 Sponsor Protocol Number: EMD121974-011 Start Date*: 2008-08-28
    Sponsor Name:Merck KGaA
    Full Title: Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination wi...
    Medical condition: Newly diagnosed, histologically proven GBM with proven methylated MGMT gene promoter status
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended) SK (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005647-24 Sponsor Protocol Number: MIA2019/CT/258 Start Date*: 2021-05-10
    Sponsor Name:Melanoma Institute Australia
    Full Title: A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain met...
    Medical condition: melanoma brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003656-31 Sponsor Protocol Number: UCL/14/0174 Start Date*: 2015-07-31
    Sponsor Name:University College London
    Full Title: Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers
    Medical condition: Locally advanced biliary tract cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10004586 Bile duct adenocarcinoma non-resectable LLT
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 02:41:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA